Georges Nembot

Most-cited papers

1. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.

   A. Chéret, C. Bacchus-Souffan, V. Avettand-Fenoël, A. Mélard +13 more

   2015Journal of Antimicrobial Chemotherapy108 citations Open access

   Semantic Scholar

   Save

2. A Single HIV-1 Cluster and a Skewed Immune Homeostasis Drive the Early Spread of HIV among Resting CD4+ Cell Subsets within One Month Post-Infection

   C. Bacchus, A. Chéret, V. Avettand-Fenoël, Georges Nembot +16 more

   2013PLoS ONE73 citations Open access

   Semantic Scholar

   Save

3. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.

   A. Chéret, Georges Nembot, A. Mélard, C. Lascoux +19 more

   2015Lancet. Infectious Diseases (Print)69 citations

   Semantic Scholar

   Save

4. Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment‐Naive HIV‐Infected Patients

   Radojka M. Savic, Aurélie Barrail-Tran, X. Duval, Georges Nembot +7 more

   2012Clinical pharmacology and therapy56 citations Open access

   Semantic Scholar

   Save

5. Adherence Profiles and Therapeutic Responses of Treatment-Naive HIV-Infected Patients Starting Boosted Atazanavir-Based Therapy in the ANRS 134-COPHAR 3 Trial

   J. Parienti, A. Barrail-Tran, X. Duval, Georges Nembot +7 more

   2013Antimicrobial Agents and Chemotherapy38 citations Open access

   Semantic Scholar

   Save

6. CD8 T-Cells from Most HIV-Infected Patients Lack Ex Vivo HIV-Suppressive Capacity during Acute and Early Infection

   C. Lécuroux, I. Girault, A. Chéret, P. Versmisse +6 more

   2013PLoS ONE25 citations Open access

   Semantic Scholar

   Save

7. COL05-02 : Résultats de l’essai OPTIPRIM-ANRS 147

   A. Chéret, Adeline Mélard, Georges Nembot, C. Lascoux +3 more

   20140 citations

   Semantic Scholar

   Save